Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Brian Booth"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1573-1576 (2023)
Externí odkaz:
https://doaj.org/article/3403c3b027e44653962206bc7f1dfc91
Autor:
Sriram Subramaniam, Stacy S. Shord, Ruby Leong, Kelly Norsworthy, Atiqur Rahman, Brian Booth, Olanrewaju Okusanya
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 5, Pp 719-722 (2023)
Externí odkaz:
https://doaj.org/article/2a874c895da64594bfffa79fa9b59a2c
Autor:
Qi Liu, Raina Mathur, Yuan Xu, Aracelis Z. Torres, Rebecca A. Miksad, Chao Liu, Haixia Smithson, Yaning Wang, Hao Zhu, Brian Booth, Shiew‐Mei Huang, Jizu Zhi, Rajeshwari Sridhara, Gideon Michael Blumenthal, Erin Larkins, Pallavi S. Mishra‐Kalyani, Donna R. Rivera, Paul G. Kluetz, Elad Sharon
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1139-1149
Autor:
Sara A. Hurvitz, Christy L. Osgood, Preeti Narayan, Laleh Amiri-Kordestani, Jennifer J Gao, Julia A. Beaver, Matthew P. Goetz, Danielle Krol, C.P. Miller, Meredith M. Regan, Erik Bloomquist, L. Mauro, Gwynn Ison, Fatima Cardoso, Brian Booth, C. Hodgdon, Vishal Bhatnagar, Richard Pazdur, Lola Fashoyin-Aje
Publikováno v:
Annals of Oncology. 32:950-953
Publikováno v:
2022 Asia-Pacific International Symposium on Electromagnetic Compatibility (APEMC).
Publikováno v:
Cancer Research. 83:3979-3979
Introduction: This research aims to characterize and evaluate the potential of two novel tandem peptides for their ability to mediate the delivery of CD44 siRNA into HER2+ breast cancer cell lines. HER2+ cancer accounts for 20%-25% of invasive breast
Autor:
Darrell R. Abernethy, Balaji Agoram, John M. Allen, Mark E. Arnold, Arthur J. Atkinson, Thomas J. Bateman, Kimberly Bergman, Brian Booth, David W. Boulton, Robert A. Branch, Gilbert J. Burckart, Mary Buschmann, Owen Carmichael, Christine Chamberlain, Ligong Chen, Charles E. Daniels, Promi Das, Jana G. Delfino, John N. Van Den Anker, Albert W. Dreisbach, Michael Dyszel, Justin C. Earp, M. Khair ElZarrad, Osatohanmwen J. Enogieru, Elimika Pfuma Fletcher, David M. Foster, Marilynn C. Frederiksen, Aleksandra Galetin, Pamela D. Garzone, Kathleen M. Giacomini, Megan A. Gibbs, Jack A Gilbert, Danijela Gnjidic, Charles T. Gombar, Denis M. Grant, Charles Grudzinskas, Bengt Hamren, Nicholas H.G. Holford, Shiew-Mei Huang, Renee Iacona, Nina Isoherranen, Denise Jin, Bridgette L. Jones, Gregory L. Kearns, Cindy Kortepeter, Elizabeth Kunkoski, S.W. Johnny Lau, Christopher Leptak, Juan J.L. Lertora, Lawrence J. Lesko, Jiang Liu, Qi Liu, Rajanikanth Madabushi, Raymond Miller, Diane R. Mould, Monica Muñoz, Thomas D. Nolin, Robert Joseph Noveck, R. Scott Obach, Michael Pacanowski, Mary F. Paine, Carl C. Peck, Anuradha Ramamoorthy, A. David Rodrigues, Malcolm Rowland, Chandrahas G. Sahajwalla, Martina Dagmar Sahre, Robert N. Schuck, Khushboo Sharma, Tristan Sissung, Catherine S. Stika, Chris H. Takimoto, Helen Tomkinson, Jack Uetrecht, Paolo Vicini, Karen D. Vo, John A. Wagner, Yaning Wang, Yow-Ming C. Wang, Peter G. Wells, Michael J. Wick, Sook Wah Yee, Ophelia Yin, Nathalie K. Zgheib, Lei Zhang, Hao Zhu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::848d2065918d75dffbea67f6015e7476
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
https://doi.org/10.1016/b978-0-12-819869-8.09990-0
Autor:
Mark E. Arnold, Brian Booth
In this chapter, we describe the importance of bioanalytical methods to drug development. These assays, measuring the active drug and metabolites, provide critical information on the exposure of the drug that is used to correlate with safety and effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e98dd61ed0b99eb654462556ad19e716
https://doi.org/10.1016/b978-0-12-819869-8.00030-6
https://doi.org/10.1016/b978-0-12-819869-8.00030-6
Autor:
Brian Booth, Lauren Stevenson, Renuka Pillutla, Michael Buonarati, Chris Beaver, Daniela Fraier, Fabio Garofolo, Sam Haidar, Rafiq Islam, Christopher James, John Kadavil, Olga Kavetska, Fumin Li, Christina Satterwhite, Natasha Savoie, Sriram Subramaniam, Nilufer Tampal, Theingi Thway, Eric Woolf, Olivier Le Blaye, Matthew Andisik, Chad Briscoe, Stephanie Cape, Arindam Dasgupta, Sally Fischer, Roger Hayes, John Kamerud, Gustavo Mendes Lima Santos, Corey Nehls, Catherine Soo, Stephen Vinter, Emma Whale, Keyang Xu, Seongeun (Julia) Cho, Anna Edmison, Sean Kassim, Thais Correa Rocha, Jan Welink, Shashi Amur, Abbas Bandukwala, Elana Cherry, Shirley Hopper, Akiko Ishii-Watabe, Susan Kirshner, Kevin Maher, Joao Pedras-Vasconcelos, Yoshiro Saito, Therese Solstad Saunders, Venke Skibeli, Daniela Verthelyi, Yow-Ming Wang, Haoheng Yan
Publikováno v:
Bioanalysis. 11:2099-2132
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA on 1–5 April 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract researc
Autor:
Jiangguo Liu, Christy L. Osgood, Jingyu Yu, A. Rahman, Patricia Keegan, Hong Zhao, B. Furmanski, Brian Booth, A. Ward, Yaning Wang, Youwei Bi
Publikováno v:
Annals of Oncology. 30:644-651
Background A nivolumab dosage regimen of 480mg intravenously (i.v.) every 4weeks (Q4W) was approved by FDA for the majority of the approved indications for nivolumab. Methods The proposed new dosage regimen was supported by pharmacokinetic modeling a